Inmed Pharmaceuticals Appoints Mr. John Bathery to Its Board of Directors

Core Insights - InMed Pharmaceuticals has appointed Mr. John Bathery to its Board of Directors, effective immediately, to enhance its strategic capabilities in drug development [1][2][4] - Mr. Bathery has over 30 years of experience in the pharmaceutical industry, with a strong background in corporate development and strategic partnerships, having managed transactions exceeding $60 billion [2][3] - The company is advancing its INM-901 program for Alzheimer's disease and INM-089 program for Age-related Macular Degeneration towards clinical readiness [3] Company Overview - InMed Pharmaceuticals focuses on developing proprietary small molecule drug candidates targeting diseases with high unmet medical needs, including Alzheimer's and ocular conditions [5] - The company has a pipeline consisting of three separate programs aimed at treating Alzheimer's, ocular, and dermatological indications [5] Leadership Changes - Mr. Bryan Baldasare will not stand for re-election at the upcoming Annual General Meeting due to increasing professional obligations [3] - Andrew Hull, Chairman of the Board, expressed confidence in Mr. Bathery's expertise to drive the company's growth and strategic collaborations [4]